arrow
K

Kuikui Jiang

Sun Yat-sen University Cancer Center
H指数:11
被引数:591

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Germline Pathogenic Variants in HER2-Positive Breast Cancer: Spectrum and Clinical Implications in a High-Risk Chinese Cohort

HER2阳性乳腺癌中的胚系致病性变异:高风险中国队列中的谱系及临床意义

2026-05-150
OAAI
HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)

HDAC抑制剂tucidinostat和节拍卡培他滨联合内分泌治疗CDK4/6抑制剂治疗后HR阳性HER2-negative晚期乳腺癌患者: 一项多中心2期研究的临床发现和探索性循环肿瘤细胞和ctDNA生物标志物分析 (SYSUCC-020试验)

2026-04-150
OAAI
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial
2024-04-012
OAAI
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment The SYSUCC-001 Randomized Clinical Trial
2021-01-05192
OAAI